Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects approximately 1% of the adult population, and involvement of extra-articular tissue occurs in approximately 40% of patients over their lifetimes.1 RA-associated pericardial disease is an uncommon complication, and surgery is the only definitive therapy—according to current literature. In this report, we present the case of…
ATLANTA—At the 2019 ACR/ARP Annual Meeting in November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards about their individual contributions to advancing rheumatology. You’ll also find a…
As Ellen M. Gravallese, MD, begins the ACR presidency, her goals include workforce expansion, improved access to care and support for members in all areas of practice.
New research seeking to describe the characteristics of undefined, systemic autoinflammatory diseases may have identified distinct subgroups, including pericarditis and intellectual impairment…
Intravenous rituximab can now be used to treat pediatric patients with GPA and MPA as young as two years old…
A patient with rheumatoid arthritis (RA) asks if diet can help ease their symptoms. Or maybe a patient with severe knee osteoarthritis (OA) seeks diet advice because they want to lose weight and relieve pressure on their joints. Although there’s no specific nutrition plan for patients with rheumatic diseases, research has shown many dietary factors…
The identification of specific transcription factors linked to the Epstein-Barr virus (EBV) provides new information on the molecular mechanisms underlying the link between EBV and autoimmune disease. A recently published study, “Transcription Factors Operate Across Disease Loci, with EBNA2 Implicated in Autoimmunity,” co-led by John B. Harley, MD, PhD; Leah C. Kottyan, PhD; and Matthew…
Apremilast was first marketed in March 2014 for the treatment of adults with psoriatic arthritis (PsA). An immunomodulating drug, which is a small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP), apremilast is administered orally. By inhibiting PDE4, intracellular cAMP levels are increased. Although the exact mechanism of action is not…
Session attendees will hear about recent successes from the Government Affairs Committee and learn how to become effective rheumatology advocates.
With innovative session formats and unique spaces that encourage learning and networking, the 2019 ACR/ARP Annual Meeting will offer exciting new opportunities for rheumatology professionals. Here’s a sneak peek…